Dataset:  lansoprazole_bioeq.csv

Source: H.A. Dugger, J.D. Carlson, W. Henderson, G.R. Erdmann, S. Mahmood Alam, 
R. Dham, Quamruzaman (2001). "Bioequivalence Evaluation of Lansoprazole 30-mg
Capsules (Lanfast and Lanzor) in Healthy Volunteers," European Journal of Pharmaceutics and
Biopharmaceutics, Vol. 51, pp.153-157.

Description: Crossover design with 26 subjects comparing test formulation Lanfast with 
reference formulation Lanzor. Formulations were determined to be bioequivalent.

Variables:
subjectID
formulation    (T=Lanfast, R=Lanzor)
AUC_0t         (Area under concentration time curve, 0-16 hours,   ng h/ml)
AUC_0inf       (  "    "        "          "    "  , extrapolated from 0-infty, ng h/ml)
C_max          (Maximum concentration, ng/ml)
T_max          (Time to maximum concentration, hours)
lambda_z       (Elimination Rate Constant)
T_0.5          (Elimination Half life, hours = sqrt(2)/lambda_z)